Polycythemia vera (PV) management has a clear therapeutic objective: maintain hematocrit <45% to reduce thrombotic risk. The evidence supporting this threshold is well established, and clinical guidelines are explicit in their recommendations. Despite this clarity, sustained hematocrit control in routine practice remains inconsistent. Patients frequently cycle above target values, undergo phlebotomy to correct elevations, and
CME is often evaluated by participation rates, satisfaction scores, and knowledge gains. These metrics are important as they demonstrate engagement and exposure. However, they do not necessarily demonstrate change. Across therapeutic areas, clinical variability persists despite widespread dissemination of guidelines and data. The disconnect reveals a fundamental design issue; many programs are built around content
Clinicians are increasingly exposed to RWE, but many lack training in study design interpretation. Break down confounding, selection bias, and applicability to practice.
Focus on diagnostic delay, symptom misattribution, and low index of suspicion. Provide strategies for red-flag recognition and referral pathways.
Address clinician difficulty interpreting biomarker data, device-generated metrics, genomics panels, and real-world evidence.
Break down Moore’s Levels 3–7 and examine why knowledge gain rarely translates into measurable patient-level outcomes.
